The randomized phase III SYNERGY II study is the first to assess the long-term safety and therapeutic efficacy of mirabegron plus solifenacin versus each monotherapy for overactive bladder (OAB). Over 12 months, the combination was well tolerated, with only a slightly higher frequency of treatment-related adverse events in the combination arm compared with mirabegron and solifenacin alone (49% versus 41% versus 44%, respectively). The combination significantly reduced the mean number of incontinence episodes and micturitions compared with each monotherapy.
References
Original article
Gratzke, C. et al. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). Eur. Urol. https://doi.org/10.1016/j.eururo.2018.05.005 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bradley, C.A. Mirabegron and solifenacin for OAB. Nat Rev Urol 15, 526 (2018). https://doi.org/10.1038/s41585-018-0049-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0049-2
